An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia
NCT ID: NCT01488162
Last Updated: 2017-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
327 participants
OBSERVATIONAL
2011-04-04
2016-10-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
NCT01392716
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
NCT01224093
Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL
NCT00180895
A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.
NCT00532129
A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
NCT01998893
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL) with first or second relapse
* Previous treatment with MabThera/Rituxan
* MabThera/Rituxan treatment planned for current relapse
Exclusion Criteria
* Life expectancy \<6 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aix-en-Provence, , France
Aix-en-Provence, , France
Albi, , France
Angers, , France
Antibes, , France
Argenteuil, , France
Arras, , France
Avignon, , France
Bayonne, , France
Béziers, , France
Béziers, , France
Blois, , France
Bobigny, , France
Bordeaux, , France
Bordeaux, , France
Boulogne, , France
Bourg-en-Bresse, , France
Brest, , France
Caen, , France
Caen, , France
Carcassonne, , France
Castelnau Lez, , France
Chalon-sur-Saône, , France
Chambéry, , France
Clermont-Ferrand, , France
Clermont-Ferrand, , France
Colmar, , France
Compiègne, , France
Corbeil-Essonnes, , France
Creil, , France
Fréjus, , France
Grenoble, , France
La Source, , France
La Tronche, , France
Le Mans, , France
Libourne, , France
Lyon, , France
Marseille, , France
Marseille, , France
Mâcon, , France
Melun, , France
Metz, , France
Metz, , France
Metz-Tessy, , France
Montauban, , France
Montpellier, , France
Mulhouse, , France
Nantes, , France
Nantes, , France
Nice, , France
Nice, , France
Nîmes, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Perpignan, , France
Perpignan, , France
Pessac, , France
Pierre-Bénite, , France
Poitiers, , France
Pontoise, , France
Reims, , France
Rennes, , France
Rennes, , France
Roubaix, , France
Rouen, , France
Saint Prient En Jarez, , France
Saint-Brieuc, , France
Saint-Germain-en-Laye, , France
Saint-Herblain, , France
Saint-Quentin, , France
Salon-de-Provence, , France
Salouël, , France
Strasbourg, , France
Strasbourg, , France
Toulon, , France
Toulon, , France
Toulouse, , France
Tours, , France
Troyes, , France
Valence, , France
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML25664
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.